Browse life science companies in Stevenage, including organisations based within the Stevenage Bioscience Catalyst ecosystem.
Automated bioreactor platform for cell and gene therapy manufacturing
microfluidX is a UK instruments company developing automated bioprocessing platforms for cell and gene therapy research and manufacturing. Its core product is a microfluidics-based bioreactor system designed for parallel cell culture process development and scalable cell expansion. The platform integrates online…
Preventing cancer therapy side effects with topical medicines
VasoDynamics is a clinical-stage pharmaceutical development company focused on preventing the debilitating side effects of cancer therapy. The company develops topical formulations targeting radiation-induced oral mucositis, dermatitis, and chemotherapy-induced hair loss, using vasoconstrictor and radioprotective…
Antibody fragment drug conjugate platform for solid tumour oncology
Antikor Biopharma is a pre-clinical stage biotechnology company developing antibody fragment drug conjugates for the treatment of solid tumours. The company's proprietary platform uses smaller antibody fragments rather than whole antibodies to achieve improved tumour penetration and faster systemic clearance compared…
Engineered bacteria to remodel the tumour microenvironment
Neobe Therapeutics is a UK synthetic biology company developing programmable live biotherapeutics that colonise solid tumours and disrupt the local microenvironment to enable immune cell infiltration. The platform engineers tumour-colonising bacteria to break down stromal barriers that exclude immune cells, aiming to…
Preclinical RNA medicines for chronic liver disease and fibrosis
Afortiori Bio is a preclinical biotechnology company developing RNA medicines for chronic liver disease, particularly liver fibrosis. Its lead programme uses Target Site Blocker RNA technology to selectively modulate gene expression in liver cells. The approach is intended to address processes contributing to fibrotic…
Lentiviral vector yield enhancement via HDAC inhibitors and producer lines
Synthistat is a biotechnology company developing technologies to increase lentiviral vector production for cell and gene therapy manufacturing. Its work combines designed histone deacetylase (HDAC) inhibitors with approaches to modify HEK293 producer cells. The company has reported early laboratory results from…
AI-guided personalised mRNA cancer vaccine development
Genevation is a biotechnology company developing personalised mRNA cancer vaccines using AI-assisted tumour neoantigen identification. Its platform analyses tumour sequencing data to select patient-specific targets and combines computational vaccine design with cell-free RNA manufacturing. The company reports…
Lentiviral gene therapy developer for tumours and rare diseases
Santo Therapeutics develops in vivo lentiviral gene therapies for cancer and rare genetic disorders. Its proprietary vector platform supports programmes including ST002, an NF2 gene-replacement therapy for NF2-related schwannomatosis. The company announced the start of an investigator-initiated clinical trial of ST002…
Open innovation life sciences campus co-located with GSK
Stevenage Bioscience Catalyst (SBC) is a not-for-profit open innovation campus and the UK's first biomedical catalyst, established in 2012 through joint funding from GSK, Wellcome and Innovate UK. Co-located with GSK's UK R&D facility, the campus hosts over 40 life science companies alongside the Cell and Gene Therapy…
In vitro respiratory and inhalation toxicology testing services
ImmuONE is a contract research company specialising in in vitro inhalation toxicology and respiratory safety assessment. The company develops and applies human alveolar macrophage and epithelial cell culture models to evaluate the safety and efficacy of inhaled compounds, providing an alternative to animal testing.…
Combinatorial stem cell screening platform for therapy development
Plasticell is a biotechnology company developing cell and gene therapies and enabling drug discovery through its proprietary platform. The technology uses bead-based combinatorial screening to test thousands of cell culture variable combinations in parallel, identifying optimised protocols for stem cell expansion,…
AAV gene therapies for rare and neurological diseases
Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus-based gene therapies for serious chronic diseases. Its lead programme is a Phase I/II gene therapy for Gaucher disease type 1, a rare lysosomal storage disorder. Further pipeline candidates target GBA1 Parkinson's disease and…
Precision oncology biotech targeting synthetic lethality in cancer
Tessellate Bio is a precision oncology company developing small molecule drugs that exploit synthetic lethality, the principle that certain genetic vulnerabilities in cancer cells can be targeted to selectively kill tumour cells. The company's lead programme targets the FANCM complex in cancers relying on Alternative…
Systemic viral immunotherapy for solid tumours
Stratosvir develops engineered viral immunotherapies for advanced solid tumours and their metastases. Its platform aims to overcome the limitations of injecting therapeutic viruses directly into tumours by enabling systemic, intravenous delivery. Within tumour tissue, the viruses are designed to replicate selectively…
Platform for controlled, repeatable cellular rejuvenation therapeutics
BioRes is a preclinical biotechnology company developing a platform for controlled, repeatable cellular rejuvenation. The company's approach aims to restore cellular function as a way of addressing the underlying biological causes of age-related decline and disease, rather than treating individual conditions in…
RNAi brain shuttle platform for neurodegenerative disease drug delivery
Aerska is a biotechnology company developing RNA interference medicines to treat, delay and prevent diseases of the brain. The company's antibody oligonucleotide conjugate platform acts as a brain shuttle, enabling RNAi therapeutics to cross the blood brain barrier and reach the central nervous system through systemic…
Targeting mitochondrial dysfunction in neurodegeneration
NRG Therapeutics is a clinical-stage neuroscience company developing small molecule inhibitors of the mitochondrial permeability transition pore as disease-modifying treatments for neurodegenerative disorders. Its lead candidate, NRG5051, entered Phase 1 clinical trials in January 2026 for ALS and Parkinson's disease.…
AI-guided CRISPR platform developing precision-bred crop varieties
Phytoform Labs is a plant biotechnology company combining artificial intelligence and CRISPR-Cas gene editing to accelerate the development of novel crop traits. Its platform models sequence-to-function relationships across plant genomes to predict beneficial DNA variants, which are implemented as transgene-free…
AI bioprocess operating system for cell and gene therapy manufacturing
Native Labs Ltd is a software company developing an AI-powered bioprocess operating system for cell and gene therapy manufacturing. The platform unifies heterogeneous manufacturing data, including bioreactor time series, multi-omics, and batch records, into standardised AI-ready datasets. Neural network models enable…
Synthetic plant metabolites for osteoarthritis and age-related disease
AKL Therapeutics is a privately held UK pharmaceutical company developing APPA, a patented oral investigational medicine combining two synthetic plant metabolites that act synergistically to target multiple signalling pathways in osteoarthritis. Animal studies have demonstrated pain reduction and delayed cartilage…